"Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) tablets are indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene."
For the treatment of Diabetic Macular Edema (DME).
The treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.
For the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
For the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with: • diet and exercise in patients for whom metformin is inappropriate due to contraindication or intolerance. • 1 to 3 oral antihyperglycemic agents (any one or combination of metformin, sulfonylurea, sodium-glucose cotransporter 2 inhibitor (SGLT2i)), when diet and exercise plus the baseline treatment does not achieve adequate glycemic control. • basal insulin with or without metformin, when diet and exercise plus basal insulin with or without metformin do not
Neoadjuvant treatment of adult patients with resectable NSCLC (tumours â‰¥4cm or node positive) when used in combination with platinum-doublet chemotherapy.